• E-mail page
• Print page
• Text size   

We've gathered a collection of patient education materials, journal articles and formulary information to help you and your at-risk patients.

Formulary Tool

Select your state and up to six health plans to determine the availability of CRESTOR^® (rosuvastatin calcium) under specific benefit plans.

> Check patient eligibility

Journal Reprints

Review findings from major studies on the safety and efficacy of CRESTOR, including the results of the METEOR trial, which demonstrate the efficacy of CRESTOR in slowing the progression of atherosclerosis.¹

> Review clinical trials

Medical Information

The information available on the AstraZeneca Medical Information for Health Care Professionals site is provided for general educational and informational purposes only.

> Find out more about the site

Web Resources

A selection of Web sites from some of the leaders in high cholesterol, atherosclerosis, and cardiovascular diseases.

> Connect to online resources

CRESTOR is indicated^#

• As an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia
• As an adjunct to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels
• CRESTOR is not indicated to reduce cardiovascular morbidity and mortality

CRESTOR is contraindicated^#

• In patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers

Important safety information about CRESTOR^#

• Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg)
• CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir
• Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever
• CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose
• It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (eg, semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume substantial quantities of alcohol
• In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%)^‡‡